Mair, Braeden AZelt, Jason G ENekesa, KiraboSaint-Georges, ZacharieDinelle, KatieAdi, MyriamRobinson, SimonMielniczuk, Lisa MShlik, JakovBeanlands, Rob SdeKemp, Robert ARotstein, Benjamin H2023-10-122023J. Nucl. Cardiol. 2023, 30(5), 2089–20951071-3581https://link.springer.com/article/10.1007/s12350-023-03338-9https://doi.org/10.1007/s12350-023-03338-9http://hdl.handle.net/10393/45542https://doi.org/10.20381/ruor-29747Cardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[11C]hydroxyephedrine, [18F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim of this study was to evaluate pharmacokinetic and metabolic properties of FBBG in target clinical cohorts.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/FlubrobenguanePETfluorine-18metabolismsympathetic nervous systemHumansPositron-Emission TomographyHeartGuanidinesCardiomyopathiesResearch Paper10.1007/s12350-023-03338-9